What is the diagnosis for a focal liver lesion that shows arterial-phase hyperenhancement with washout on portal-venous and delayed phases and fluorodeoxyglucose (FDG) avidity?

Hepatocellular Carcinoma (HCC)

The most likely diagnosis is hepatocellular carcinoma (HCC), particularly in the setting of chronic liver disease or cirrhosis. The imaging pattern of arterial-phase hyperenhancement with washout in portal venous and delayed phases represents the classic radiological hallmark of HCC 1, 2.

Diagnostic Reasoning

The combination of imaging features you describe is highly specific for HCC:

• Arterial phase hyperenhancement (APHE) followed by washout in portal venous/delayed phases is the established vascular hallmark that defines HCC on multiphasic CT or MRI 1, 2
• This pattern reflects the unique vascular transformation during hepatocarcinogenesis, where HCC develops arterial neovascularization as its dominant blood supply 1

FDG Avidity: A Critical Distinguishing Feature

The presence of FDG avidity adds important diagnostic nuance:

• Standard HCC typically shows LOW FDG uptake, which is why FDG-PET is not recommended for early HCC diagnosis 1, 3
• High FDG avidity suggests more aggressive HCC subtypes, including:
  • Poorly differentiated HCC (mean SUVmax 5.7 ± 2.3) 4
  • Sarcomatous HCC (SUVmax 14.1-25.0) 4
  • Combined hepatocellular-cholangiocarcinoma (SUVmax 9.9-13.0) 4

This FDG-avid pattern indicates a more aggressive tumor with worse prognosis and potentially different treatment considerations.

Differential Diagnosis Considerations

While HCC is most likely, the imaging pattern requires careful evaluation to exclude mimickers:

Intrahepatic Cholangiocarcinoma (CCA)

• Can show arterial hyperenhancement with washout 1
• Key difference: CCA typically demonstrates early and strong washout (before 60 seconds), whereas HCC shows delayed and mild washout (≥60 seconds) 5, 6
• CCA may show targetoid appearance or marked T2 hyperintensity, which should exclude HCC diagnosis 2

Combined HCC-Cholangiocarcinoma

• Shows high FDG avidity (SUVmax 9.9-13.0) 4
• May require biopsy for definitive diagnosis
• Important to identify as treatment approach differs

Diagnostic Algorithm

For cirrhotic patients or those with chronic hepatitis B/C:

1. Lesion ≥1 cm with APHE + washout on CT/MRI = Definite HCC 2

   • No biopsy needed if typical features present
   • Specificity 91-100% 2

2. Exclude HCC mimickers by checking for:

   • Marked T2 hyperintensity (suggests hemangioma or CCA) 2
   • Targetoid appearance on DWI or contrast images (suggests CCA) 2
   • Rim arterial enhancement (suggests CCA or metastasis) 5
   • Peripheral eosinophilia (focal eosinophilic liver disease can mimic HCC) 2

3. If atypical features present:

   • Consider second-line imaging (alternative modality) 2
   • Multidisciplinary discussion 1
   • Biopsy if diagnosis remains uncertain 1

For non-cirrhotic patients:

• Non-invasive criteria are NOT validated 3, 7
• Biopsy is required for definitive diagnosis 1

Critical Pitfalls to Avoid

1. Do not apply non-invasive HCC criteria to non-cirrhotic patients - specificity drops significantly 3, 7

2. Do not diagnose HCC if lesion shows:

   • Marked T2 hyperintensity 2
   • Targetoid appearance 2
   • Rim APHE 5

3. High FDG avidity is NOT typical for well-differentiated HCC - this finding should prompt consideration of aggressive HCC variants or alternative diagnoses 4

4. Timing of washout matters: Early washout (<60 seconds) favors cholangiocarcinoma or metastasis over HCC 5, 6

Clinical Implications

Given the FDG avidity in your case:

• Expect more aggressive tumor biology 4
• Consider biopsy even in cirrhotic patients to confirm histology and assess for sarcomatous change or combined HCC-CCA 4
• Staging should include assessment for extrahepatic metastases given aggressive features 1
• Treatment planning requires multidisciplinary discussion including hepatobiliary surgery, transplant surgery, and oncology 1